Clinical Study Results
The table below shows the most common adverse reactions that happened during this
study. The researchers thought that these were related to the study treatment.
Most common adverse reactions during the study
RDEA3170, RDEA3170,
febuxostat, and febuxostat, and
dapagliflozin a placebo
(out of 35 (out of 36
participants) participants)
Diarrhea 2.9% (1) 2.8% (1)
Passing gas 0.0% (0) 2.8% (1)
Headache 0.0% (0) 2.8% (1)
Nausea 0.0% (0) 2.8% (1)
How has this study helped patients and researchers?
This study helped researchers learn how treatment with RDEA3170, febuxostat, and
dapagliflozin affects uric acid levels in people who have high levels of uric acid in their
blood.
Researchers look at the results of many studies to decide which treatments work best
and are safest. This summary shows only the main results from this one study. Other
studies may provide new information or different results.
Further clinical studies with RDEA3170 are planned.
7